subgenus Sarbecovirus in the Orthocoronavirinae subfamily [3] [4] [5] [6] [7] .
Phylogenetic studies of the new virus showed it shared about 79% nucleotide homology with SARS-CoV 4-7 , as well as to two SARS-like coronaviruses isolated from Chinese horseshoe bats (Rhinolophus sinicus) in Zhoushan, with which it shared 89% nucleotide homology 3, [5] [6] [7] [8] , and to a third SARS-like coronavirus from an Intermediate horseshoe bat (R. affinis), with which it shared 96% nucleotide homology 4, 9 . Based on established practice, the new virus was named SARS-CoV-2 by the Coronavirus Study Group of the International Committee for the Taxonomy of Viruses 10 , and the disease it causes as COVID-19 by WHO 11 .
How this virus moved from animal to human populations is yet to be determined. The outbreak clearly began epidemiologically at the Wuhan market, and a number of environmental samples from around the live animal section of the market were subsequently found to be positive for SARS-CoV-2 12 , but based on current evidence, it may not have actually emerged in the market. The earliest recognised case of infection with SARS-CoV-2 was an elderly and infirm man who developed symptoms on 1 December 2019.
None of his family members became infected, and the source of his virus remains unknown 13 . Furthermore, 14 of the first 41 cases had no contact with the seafood market 13 . In another report, five of the first seven cases of COVID-19 had no link to the seafood market 14 .
Thus, it seems very likely that the virus was amplified in the market, but the market might not have been the site of origin nor the only source of the outbreak. A recent phylo-epidemiological study has suggested that the virus was circulating but unrecognised in November, and was imported to the seafood market from elsewhere, where it subsequently was amplified 15 .
Angiotensin-converting enzyme II (ACE2) was known to be the cell receptor for SARS-CoV, and also for some SARS-like bat coronaviruses 16 . Sequence studies found that the receptor-binding domain of the SARS-CoV-2 virus was sufficiently similar to that of SARS-CoV to indicate it could efficiently use the human ACE2 receptor for entry to human cells 6, 7 . Infectivity experiments were undertaken with HeLa cells expressing or not expressing ACE2 from humans, bats, civets, pigs and mice, and the results confirmed that SARS-CoV-2 virus was able to use entry receptors on all ACE2-expressing cells other than mice 5 . Molecular modelling has indicated that the binding affinity of SARS-CoV-2 to ACE-2 may be even higher than that of SARS-CoV and it may therefore be more efficient at infecting human cells 17 [3] [4] [5] [6] [7] , but this information was not widely available until a sequence was reported on 12 January 2020. Interestingly, this was the first time that NGS had alerted the world to a new zoonotic virus before the virus had been isolated, and it suggests that a new procedure for reporting outbreaks based on NGS rather than pathogen isolation and identification needs to be considered 19 .
The resulting information flow was a great improvement over the experience with SARS-CoV in 2003, but it is important to continue improving this as the lack of the earliest possible information about the sequences slowed down the development of diagnostics and preparedness capacity. This lack of early information may have extended to case notifications, as no cases were reported between 1 and 17 January 2020, but modelling suggested there may have been over 450 cases unreported in that time 20 , and indeed a number of such cases were subsequently confirmed retrospectively 14 .
Transmission Human-to-human transmission of SARS-CoV-2 has been widely shown in health care, community and family settings. The dominant mode of transmission is from the respiratory tract via droplets or indirectly via fomites, and to a lesser extent via aerosols. In addition, as SARS-CoV and MERS-CoV can infect the human gastrointestinal tract 21, 22 , it has been suggested that faecal-oral spread may occur for SARS-CoV-2 23 . The reproduction number (Ro) is generally thought to be between 2.0 and 2.8 20,24-27 , although higher reproduction numbers have been suggested in some reports. The mean incubation time appears to be between 4.75 and 7 days 20,23,24,26,28 , ranging from 3 days to an upper limit of around 11-14 days. There is increasing knowledge about the virus load. In one study of symptomatic patients, higher viral loads were detected soon after symptom onset, with the viral loads higher in the nose than in the throat. In a single asymptomatic patient, the viral load was similar to the symptomatic patients 29 . In a second and more detailed study, the virus load was investigated over Hot Topic consecutive days in two patients from the time of their hospitalisation, with serial samples throat swabs, sputum, urine and stools. The viral loads peaked around 5-6 days after symptom onset, with 10 4 to 10 7 copies/mL. The authors also studied the viral loads in throat swabs, sputum and stool samples in other patients, and found viral loads were as high as 10 11 copies/mL in throat samples, but with a median of 7.99 Â 10 4 , and 7.52 Â 10 5 in sputum. In addition, virus was detected by RT-PCR in stools from 9 of 17 confirmed cases, but at titres lower than in respiratory samples 30 . Several studies have indicated that transmission may occur during the incubation period 31, 32 and from asymptomatic or very mild infections 29, 33, 34 .
There are a number of important questions still to be answered about the transmission dynamics. These include information about the infectivity during the incubation period; the length of time and virus load during incubation and during the symptomatic period of virus shedding; the incidence and infectiousness of asymptomatic cases, the risk of vertical transmission from mother to fetus 35 , and other modes of transmission, such as from faeces, saliva and urine.
There is some evidence that virus can be isolated from saliva 36 and while the initial family cluster found no evidence of virus in stools or urine 8 , it has since been detected in faeces by PCR in other patients 30, 37, 38 and cultured in one patient, but there has been no evidence of virus in urine. The number of mild or asymptomatic cases has not been determined and relatively few cases have been recorded, but it is probable that current figures only see the tip of the iceberg, and many cases remain undiagnosed 19 . They pose the greatest threat for increased virus spread 27 . Information is also needed on the stability of the virus in the environment to better determine transmission risks, and especially the survival of the virus in aerosols and on hard surfaces under different conditions of temperature and humidity.
Clinical features
It has become clear that asymptomatic infections and minimally symptomatic infections occur with this virus. Exactly how frequently is not yet known as that requires serological studies that have yet to be undertaken. The initial reports of the illness were heavily The case fatality rates have varied depending on the population affected. Initial estimates that were based on severely ill patients were high, but more recent estimates are around 2.3% on average, but significantly higher in the elderly and particularly those aged 80 years and over 41 . As many milder or asymptomatic infections are likely to have been missed, the mortality rate is expected to be lower than published figures as more information becomes available.
Disease in paediatric patients appears to be rare, and when it occurs, very mild, but the role of children in transmission remains unknown.
More extensive and detailed studies are needed to understand the full spectrum of illness caused by this virus, the pathogenesis of disease, especially the lung disease, and the longer-term morbidity in survivors. The possibility of persistent and recurring infections, especially in immunocompromised patients, is unknown; we still have very limited data on the importance of pre-existing morbidities; more information is urgently needed on the disease in pregnancy and the potential for infection of the fetus; and we don't understand the effect of past exposure to other coronaviruses on modifying disease severity.
Diagnostic tests
Clinical diagnosis has largely been based on clinical and exposure history, and laboratory and chest imaging findings. The laboratory findings will vary with the severity of disease, but a low lymphocyte count is common and persisting low counts is associated with poorer outcomes 13, 39, 40 . Testing for other respiratory pathogens should be undertaken to exclude viral and bacterial co-infections. to identify any genetic drift that may affect test sensitivity. We also need to be able to transfer the tests onto platforms that can be delivered outside major laboratories, in resource poor settings, near to the patient, and quickly. The lack of serological assays hampers our ability to understand the true epidemiology of this virus and its impact, and to identify PCR-negative infections. This Australian collaboration is hoping to have the vaccine ready for use before the end of 2021.
Detection of the virus has been based on PCR, with various assays

Therapeutics and vaccines
Current status
The international public health response to COVID-19 has largely been based on measures that have proved successful for many other outbreaks over past decadesrapid identification, management and isolation of cases; identification and follow up of contacts; quarantine measures; social distancing; infection prevention and control in health care settings; community containment; and transparent risk communication; as well as a 14-day quarantine period on travellers from China or who have had links to ongoing transmission sites or known cases, such as the cruise liner in Japan.
Australia's response has been similar, and to date has been moderately successful in limiting the number of chains of transmission in NSW, Queensland and Victoria, whereas most cases elsewhere have been in returning travellers or their close contacts. Table 1 shows cumulative cases in Hubei, elsewhere in China, and in other countries on a weekly basis between 21 January and 9
March, and shows the rapid rise in cases in China, particularly in Hubei Province, followed by a slowing down over the past 2 weeks, and a continuing rise in cases outside China with more and more countries reporting cases. As of 9 March, 105 countries had reported cases, but only three countries accounted for nearly 75% of the cases; South Korea with 7382 cases, Italy with 7375 cases, and Iran with 6566, and cases have been reported from all Although WHO finally called the COVID-19 a pandemic on 11 March, in many respects it had already begun. This was presaged by the observation that more new cases were reported from the rest of the world than from China for the first time on 28 February, and in addition, secondary and tertiary chains of transmission have been reported in increasing numbers of countries. The Australian Government has already recognised this, and has instituted its emergency response plan and is now operating on the basis that the pandemic is here. 
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